What Do We Know About the Safety of OADs in Post-ACS Patients? Exploring Evidence from Recent Outcomes Studies - European Medical Journal

What Do We Know About the Safety of OADs in Post-ACS Patients? Exploring Evidence from Recent Outcomes Studies

Diabetes

At a Takeda-sponsored symposium held at the 51st Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, on the 14th September 2015, Prof Faiez Zannad of the University of Lorraine and CHU, Vandoeuvre-lès-Nancy, France, provides an overview of results from clinical trials investigating cardiovascular outcomes in patients with Type 2 diabetes treated with oral antidiabetic drugs.

Three trials have assessed the cardiovascular safety of DPP-4 inhibitors, although the EXAMINE study was the only one to actively include acute coronary syndrome patients at high risk of cardiovascular disease.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>